home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc. From 05/03/22

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Website: xortx.com
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - ATNF, CYN and BWV among mid-day movers

Gainers: Sonoma Pharmaceuticals (SNOA) +29%. Blue Water Vaccines (BWV) +32%. XORTX Therapeutics (XRTX) +27%. Eqonex  (EQOS) +21%. TETRA Technologies (TTI) +20%. Enovix (ENVX) +18%. JAKKS Pacific (JAKK) +18%. Blue Apron Holdings (APRN) +17%. Borr Drilling (BORR) +16%. Western Digital Corp...
XRTX - Sonoma, XORTX top healthcare gainers; Spero, Semler Scientific lead losers' pack

Gainers: Sonoma Pharmaceuticals (SNOA) +42%. XORTX Therapeutics (XRTX) +18%. Retractable Technologies (RVP) +14%. Catalent (CTLT) +12%. Field Trip Health (FTRP) +5%. Losers: Spero Therapeutics (SPRO) -61%. Semler Scientific (SMLR) -23%. Galmed Pharmaceu...

XRTX - XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial

CALGARY, Alberta, May 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce t...

XRTX - XORTX Receives Small and Medium Enterprise Status for the European Union

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
XRTX - XORTX Receives No Objection Letter from Health Canada

CALGARY, Alberta, April 12, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...

XRTX - XORTX Announces Grant of US Patent

CALGARY, Alberta, April 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...

XRTX - XORTX files application with FDA for trial of XRx-008 in kidney disease

XORTX Therapeutics (OTCQB:XRTXF) filed an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow a clinical study of XRx-008 to treat progressing kidney disease due to autosomal dominant polycystic kidney disease (ADPKD). The IND contains the protocol f...
XRTX - XORTX Files IND with US FDA

● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX I TSXV: XRTX I Frankfurt: ANU), a pharmaceutical ...

XRTX - VICR, AEHL and ADTH among mid-day movers

Gainers: Creative Medical Technology Holdings CELZ +74%. 4D pharma LBPS +26%. XORTX Therapeutics (XRTX) +26%. Clear Secure YOU +24%. Alpha Tau Medical (DRTS) +21%. Waterdrop WDH +21%. Cenntro Electric Group CENN +20%. Femasys FEMY +20%. Q&K International Grou...

XRTX - XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney diseas...
Previous 10 Next 10